Literature DB >> 10027326

Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.

M Raderer1, G Hamilton, A Kurtaran, J Valencak, I Haberl, O Hoffmann, G V Kornek, F Vorbeck, M H Hejna, I Virgolini, W Scheithauer.   

Abstract

Fourteen patients with metastatic pancreatic adenocarcinoma were treated with the long-acting somatostatin (SST) analogue lanreotide. No objective response was obtained, and the median survival was 4 months (range 1.8-7 months). Pancreatic cancer could not be visualized by means of SST-receptor (R) scintigraphy in our patients. In vitro data also demonstrated absence of SSTR2 expression, suggesting pancreatic cancer not to be a potential target for treatment with SST analogues.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10027326      PMCID： PMC2362412          DOI： 10.1038/sj.bjc.6690084

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  19 in total

Review 1.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

2.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

3.  Somatostatin analogue phase I trials in neuroendocrine neoplasms.

Authors:  L Anthony; D Johnson; K Hande; M Shaff; S Winn; M Krozely; J Oates
Journal:  Acta Oncol       Date:  1993       Impact factor: 4.089

Review 4.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

5.  Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160.

Authors:  Y Qin; A V Schally; G Willems
Journal:  Int J Cancer       Date:  1992-11-11       Impact factor: 7.396

6.  Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research.

Authors:  M Huguier; G Samama; J Testart; S Mauban; A Fingerhut; J Nassar; S Houry; D Jaeck; P De Mestier; J P Favre
Journal:  Am J Surg       Date:  1992-10       Impact factor: 2.565

7.  Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro.

Authors:  G Weckbecker; R Liu; L Tolcsvai; C Bruns
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

8.  Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study.

Authors:  L Canobbio; F Boccardo; D Cannata; P Gallotti; R Epis
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

9.  Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas.

Authors:  J C Reubi; U Horisberger; C E Essed; J Jeekel; J G Klijn; S W Lamberts
Journal:  Gastroenterology       Date:  1988-09       Impact factor: 22.682

10.  Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.

Authors:  J G Klijn; A M Hoff; A S Planting; J Verweij; T Kok; S W Lamberts; H Portengen; J A Foekens
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640
View more
  7 in total

1.  Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival.

Authors:  Donghui Li; Motofumi Tanaka; F Charles Brunicardi; William E Fisher; Richard A Gibbs; Marie-Claude Gingras
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

2.  Systemic therapy for metastatic pancreatic adenocarcinoma.

Authors:  Ben Lawrence; Michael Findlay
Journal:  Ther Adv Med Oncol       Date:  2010-03       Impact factor: 8.168

3.  Gene transfer of somatostatin receptor type 2 by intratumoral injection inhibits established pancreatic carcinoma xenografts.

Authors:  Zhi-Yong Du; Ren-Yi Qin; Wei Xia; Rui Tian; Manoj Kumar
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

4.  Effect of octreotide on human pancreatic cancer cells after transfected with somatostatin receptor type 2 gene.

Authors:  Zheng-Ren Liu; Ren-Yi Qin; Gao-Song Wu; Qing Chang; Da-Yu Wang; Sheng-Quan Zou; Fa-Zu Qiu
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

5.  Octreotide uptake in intracranial metastasis of pancreatic ductal adenocarcinoma origin in a patient with a prolonged clinical course.

Authors:  Rama Marepaily; Dan Micheals; Andrew Sloan; James Hatfield; Volkan Adsay; Richard Joyrich; Nadeem Ullah; Martin Tobi
Journal:  Dig Dis Sci       Date:  2008-11-05       Impact factor: 3.199

6.  Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer.

Authors:  Min Li; Xiaochi Wang; Wei Li; Fei Li; Hui Yang; Hao Wang; F Charles Brunicardi; Changyi Chen; Qizhi Yao; William E Fisher
Journal:  Cancer Sci       Date:  2008-09-22       Impact factor: 6.716

7.  Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesis.

Authors:  Ren-Yi Qin; Ru-Liang Fang; Manoj Kumar Gupta; Zheng-Ren Liu; Da-Yu Wang; Qing Chang; Yi-Bei Chen
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.